Voyager Therapeut (VYGR) Stock Price, Quote & News

Company Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neu...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 259 5340

Website: www.voyagertherapeutics.com

Address:

75 Hayden Avenue, Lexington, United States

OpenOutcrier May. 13 at 12:18 PM

$VYGR (+5.5% pre) Voyager Therapeutics (VYGR) Reports Positive Findings for Alzheimer's Gene Therapy https://ooc.bz/l/102066

0 · Reply

DARKP00L May. 13 at 10:10 AM

$VYGR 06:10 on May. 13 2026 Voyager Therapeutics' VY1706 Tau Silencing Gene Therapy Well Tolerated At Highest Dose, Reduces Tau Up To 64% In NHPs; Alzheimer's Clinical Trial Expected H2 2026 #tradeideas

0 · Reply

gookvook May. 13 at 5:47 AM

$RKLB $LUNR $VYGR

1 · Reply

ivanhoff May. 11 at 3:20 PM

Space stocks like $RKLB and $LUNR have been on fire in anticipation of SpaceX IPO next month. Lesser-knows space stocks like $VYGR might also get some buzz ahead and around that widely-expected IPO.

4 · Reply

tumanako May. 11 at 10:08 AM

$VYGR Insitutional accumulations

0 · Reply

pickens1 May. 8 at 2:59 PM

$VYGR Voyager reiterates a $172 million cash position providing runway into 2028.

0 · Reply

NorthStarStats Apr. 19 at 10:53 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. We aren't out of the wood yet. Be careful this coming week. $GPN Score 98, $MRNA Score 98, $SEIC Score 97, $VYGR Score 95, $VTGN Score 95

0 · Reply

tumanako Apr. 18 at 4:28 AM

$VYGR Buy and Buy.

0 · Reply

NorthStarStats Apr. 16 at 1:19 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. We're seeing renewed confidence in the market and excitement over earning seasons. $LEGN Score: 100, $MORN Score: 98, $SDGR Score: 98, $VYGR Score: 98, $TSLA Score: 98

0 · Reply

tumanako Mar. 20 at 9:31 PM

$VYGR Investor Businss Daily identified as a cup with handle. What other stocks can you find such bullish pattern in today's market?

0 · Reply

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

2026-05-07T21:41:13.000Z - 5 days ago

Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)

May 7, 2026, 4:01 PM EDT - 5 days ago

Voyager Reports First Quarter 2026 Financial and Operating Results

2026-04-28T12:55:45.000Z - 15 days ago

Voyager Therapeutics management to meet with Oppenheimer

Apr 27, 2026, 4:31 PM EDT - 15 days ago

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

2026-04-10T20:55:57.000Z - 4 weeks ago

Voyager Therapeutics management to meet with Oppenheimer

Mar 18, 2026, 12:30 PM EDT - 7 weeks ago

Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

2026-03-09T20:10:45.000Z - 2 months ago

Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)

Mar 9, 2026, 4:01 PM EDT - 2 months ago

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 26, 2026, 3:20 PM EST - 2 months ago

Voyager Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 9, 2026, 8:00 AM EST - 3 months ago

Voyager to Present at Upcoming Investor Conferences

2025-11-12T15:40:31.000Z - 6 months ago

Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

Nov 11, 2025, 3:20 PM EST - 6 months ago

Voyager Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-10T21:10:18.000Z - 6 months ago

Voyager Therapeutics files $400M mixed securities shelf

2025-11-10T18:25:24.000Z - 6 months ago

Voyager Therapeutics price target lowered to $11 from $12 at Leerink

2025-11-10T13:17:23.000Z - 6 months ago

Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)

2025-11-10T13:17:10.000Z - 6 months ago

Voyager Therapeutics expects cash to fund operations into 2028

2025-11-10T13:10:09.000Z - 6 months ago

Voyager Therapeutics, Transition Bio entered into drug discovery collab

Nov 10, 2025, 8:01 AM EST - 6 months ago

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

Nov 10, 2025, 8:01 AM EST - 6 months ago

Voyager Reports Third Quarter 2025 Financial and Operating Results

Sep 9, 2025, 9:05 AM EDT - 8 months ago

Voyager Therapeutics Transcript: Baird Global Healthcare Conference 2025

Sep 2, 2025, 4:00 PM EDT - 9 months ago

Voyager Therapeutics Transcript: Citi's Biopharma Back to School Conference

2025-08-07T13:13:29.000Z - 9 months ago

Voyager Therapeutics price target lowered to $8 from $9 at Wedbush

2025-08-06T20:33:20.000Z - 9 months ago

Voyager Therapeutics reports Q2 EPS (57c), consensus (52c)

Aug 6, 2025, 4:01 PM EDT - 9 months ago

Voyager Reports Second Quarter 2025 Financial and Operating Results

2025-07-16T11:06:32.000Z - 10 months ago

Voyager Therapeutics continues expansion of its AD franchise

Jul 16, 2025, 7:00 AM EDT - 10 months ago

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Jun 17, 2025, 7:00 AM EDT - 11 months ago

Voyager Therapeutics Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

2025-05-15T11:22:40.000Z - 1 year ago

Voyager Therapeutics demonstrates ALPL receptor-mediated BBB transport

May 15, 2025, 7:00 AM EDT - 1 year ago

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

2025-05-06T20:11:39.000Z - 1 year ago

Voyager Therapeutics reports Q1 EPS (53c), consensus (44c)

May 6, 2025, 4:01 PM EDT - 1 year ago

Voyager Reports First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

2025-03-31T11:20:50.000Z - 1 year ago

Voyager Therapeutics announces new data from two preclinical programs

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Mar 19, 2025, 11:00 AM EDT - 1 year ago

Voyager Therapeutics Transcript: Virtual CNS Forum

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:01 PM EDT - 1 year ago

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 4, 2025, 7:00 AM EST - 1 year ago

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

Mar 3, 2025, 1:50 PM EST - 1 year ago

Voyager Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease

Feb 25, 2025, 7:00 AM EST - 1 year ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Feb 11, 2025, 2:40 PM EST - 1 year ago

Voyager Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 7:00 AM EST - 1 year ago

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Nov 18, 2024, 9:45 AM EST - 1 year ago

Voyager Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 2:00 PM EST - 1 year ago

Voyager Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Voyager Reports Third Quarter 2024 Financial and Operating Results

Nov 5, 2024, 7:00 AM EST - 1 year ago

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Sep 11, 2024, 1:25 PM EDT - 1 year ago

Voyager Therapeutics Transcript: Baird's 2024 Global Healthcare Conference

Sep 5, 2024, 1:30 PM EDT - 1 year ago

Voyager Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:01 PM EDT - 1 year ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 14, 2024, 9:30 AM EDT - 1 year ago

Voyager Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Jun 27, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 1:35 PM EDT - 2 years ago

Voyager Therapeutics Transcript: TD Cowen Genetic Medicines & RNA Summit

Jun 13, 2024, 4:01 PM EDT - 2 years ago

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

May 16, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings Call Transcript: Q1 2024

May 13, 2024, 4:01 PM EDT - 2 years ago

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

May 8, 2024, 6:00 AM EDT - 2 years ago

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

May 6, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

OpenOutcrier May. 13 at 12:18 PM

$VYGR (+5.5% pre) Voyager Therapeutics (VYGR) Reports Positive Findings for Alzheimer's Gene Therapy https://ooc.bz/l/102066

0 · Reply

DARKP00L May. 13 at 10:10 AM

0 · Reply

gookvook May. 13 at 5:47 AM

$RKLB $LUNR $VYGR

1 · Reply

ivanhoff May. 11 at 3:20 PM

Space stocks like $RKLB and $LUNR have been on fire in anticipation of SpaceX IPO next month. Lesser-knows space stocks like $VYGR might also get some buzz ahead and around that widely-expected IPO.

4 · Reply

tumanako May. 11 at 10:08 AM

$VYGR Insitutional accumulations

0 · Reply

pickens1 May. 8 at 2:59 PM

$VYGR Voyager reiterates a $172 million cash position providing runway into 2028.

0 · Reply

NorthStarStats Apr. 19 at 10:53 PM

0 · Reply

tumanako Apr. 18 at 4:28 AM

$VYGR Buy and Buy.

0 · Reply

NorthStarStats Apr. 16 at 1:19 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. We're seeing renewed confidence in the market and excitement over earning seasons. $LEGN Score: 100, $MORN Score: 98, $SDGR Score: 98, $VYGR Score: 98, $TSLA Score: 98

0 · Reply

tumanako Mar. 20 at 9:31 PM

$VYGR Investor Businss Daily identified as a cup with handle. What other stocks can you find such bullish pattern in today's market?

0 · Reply

OfficialStocktwitsUser Mar. 20 at 6:31 PM

$VYGR RSI: 43.11, MACD: 0.0270 Vol: 0.40, MA20: 4.14, MA50: 3.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BiotechButterflies Mar. 17 at 8:38 PM

$VYGR Ended 2025 with cash position of $202 million, expected to maintain runway into 2028.... and still has market cap of only about $250M... I know the science could be a long shot... but hey...

0 · Reply